Profile photo

Lung Cancers Today

Pulmonology

Lung Cancers Today features breaking news, commentary, expert interviews, and more for practicing oncologists treating lung malignancies.

2024: An Eventful Year in Lung Cancer Treatment and Research

Dear readers,

With the end of the year fast approaching, we’re reflecting on an eventful year in lung cancer research and treatment.

From the American Society of Clinical Oncology Meeting—which even inspired the #ASCOLung hashtag with its wealth of lung cancer data—to the IASLC World Conference on Lung Cancer and the European Society of Medical Oncology Congress, this year has been filled with practice-changing advancements in lung cancer. Beyond the data presented at major medical meetings, it’s also been a busy year for regulatory filings and approvals in lung cancer, with more than a dozen approvals by the U.S. Food and Drug Administration so far in 2024. And last, but certainly not least, this year’s Lung Cancer Awareness Month was a true testament to the strength and dedication of the community, with the many critical efforts to raise awareness and inspire action.

With all the progress made in the field this year, we hope you’ll join us in reflecting on some of the key moments of the year as we count down to 2025.

Until next year,

Lung Cancers Today Editors

Articles
  • Mashup Score: 2
    Dr. Ramalingam Discusses How LAURA Established a 'New Standard of Care' | Docwire News - 5 month(s) ago

    The Two Onc Docs joined us at the 2024 American Society of Clinical Oncology Annual Meeting to interview Suresh S. Ramalingam, MD, FACP, FASCO, about his plenary presentation on the practice-changing LAURA study. The trio unpacked the data, the trial design, and what the LAURA study means for the future of oncology during a must-watch video interview.

    Tweet Tweets with this article
    • Profile photo of Lung_Cancers
      Lung_Cancers

      🗨️ What are the clinical implications of the practice-changing #LAURA study?🌟 In this video, the @TwoOncDocs interview @RamalingamMD about his plenary presentation on the phase 3 trial during #ASCO24! ➡️ Watch now: https://t.co/wW4NdkNWit#NSCLC #lcsm #ASCOLung https://t.co/pGr0aW1bDi